Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Test Rapidly Identifies Five Candida Species

By LabMedica International staff writers
Posted on 29 Sep 2008
An easy-to-use diagnostics platform rapidly identifies Candida yeast species directly from positive blood cultures. More...


The new assay, peptide nucleic acid fluorescence in situ hybridization (PNA FISH), is a highly sensitive, and specific assay that uses PNA probes to target species-specific ribosomal RNA (rRNA) in bacteria and yeasts.

Called the Yeast Traffic Light, the assay is the latest addition to AdvanDx's (Woburn, MA, USA) easy-to-use, molecular-based PNA FISH diagnostics platform that provides rapid identification of bloodstream pathogens in hours instead of days. Laboratories can identify, in a single Yeast Traffic Light test, up to five Candida species directly from positive blood cultures including C. albicans and/or C. parapsilosis, C. tropicalis, and C. glabrata and/or C. krusei in hours instead of days, enabling clinicians to provide early, effective and appropriate antifungal therapy for patients afflicted with Candidemia.

The results of the test indicate the yeast responsible for the infection; green fluorescing cells indicate C. albicans and/or C. parapsilosis; yellow fluorescing cells indicate C. tropicalis; and red fluorescing cells are C. glabrata and/or C. krusei.

It is important to identify the Candida species because they display varying resistance to commonly used antifungal agents. C. albicans and C. parapsilosis are generally susceptible to the antifungal drug fluconazole, C. tropicalis may display intermediate resistance to the drug while C. glabrata and C. krusei have the highest level of fluconazole resistance. Recent reports indicate that caspofungin, a newer and more expensive broad-spectrum antifungal drug, may be less potent against C. parapsilosis.

Candidemia, a bloodstream infection caused by Candida species, is one of the most serious nosocomial infections, afflicting over 24,000 patients every year in the United States alone. Immunocompromised transplantation, oncology, and AIDS patients are especially at risk for contracting Candida infections with mortality rates as high as 50%. Conventional methods for identifying the pathogen can take up to five days or more.

AdvanDx has received U.S. Food and Drug Administration (FDA; Rockville, MD, USA) 510(k) clearance of the Yeast Traffic Light PNA FISH to identify Candida yeast species directly from positive blood cultures.

Related Links:
AdvanDx
U.S. Food and Drug Administration



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.